MCC950 . sodium salt

CHF 50.00
In stock
AG-CR1-3615-M0011 mgCHF 50.00
AG-CR1-3615-M0055 mgCHF 90.00
AG-CR1-3615-M01010 mgCHF 140.00
More Information
Product Details
Synonyms MCC950; CP-456,773; CRID3; 1-(1,2,3,5,6,7-Hexahydro- s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]urea
Product Type Chemical
Properties
Formula

C20H23N2NaO5S

MW 426.5
CAS 256373-96-3
Purity Chemicals ≥97% (HPLC)
Appearance Crystalline solid.
Solubility Soluble in water (10mg/ml), DMSO (10mg/ml), dimethyl formamide or ethanol (1mg/ml).
Identity Determined by 1H-NMR.
InChi Key SNIGCXULUAXYGW-UHFFFAOYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent, selective and orally available NLRP3 inflammasome inhibitor.
  • Blocks the release of IL-1β in macrophages primed with LPS and activated with ATP or nigericin, but it does not inhibit NLRP1, NLRC4, AIM2, TLR2 signaling or priming of NLRP3.
  • Prevents oligomerization of ASC in cells stimulated with LPS and nigericin.
  • Active in vivo, blocking the production of IL-1β and enhancing survival in mouse models of multiple sclerosis and cryopyrin-associated periodic syndrome (CAPS). Also active in ex vivo samples from individuals with Muckle-Wells syndrome.
  • Potential therapeutic agent for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases.
Product References
  1. Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing: R.E. Laliberte, et al.; J. Biol. Chem. 278, 16567 (2003)
  2. Novel synthesis of 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methylethyl)furan-2-sulfonyl]urea, an antiinflammatory agent: F.J. Urban, et al.; Synth. Commun. 33, 2029 (2003)
  3. The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes: R.C. Coll, et al.; PLoS One 6, e29539 (2011)
  4. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases: R.C. Coll, et al.; Nat. Med. 21, 248 (2015)
  5. Taming the inflammasome: M. Levy, et al.; Nat. Med. 21, 213 (2015)
  6. The Nlrp3 inflammasome admits defeat: C.J. Gross & O. Gross; Trends Immunol. 36, 323 (2015)
  7. P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy: M.G. Khalafalla, et al.; J. Biol. Chem. 292, 16626 (2017)
  8. Inhibition of the NOD-like receptor protein 3 inflammasome Is protective in juvenile influenza A virus infection: B.M. Coates, et al.; Front. Immunol. 8, 782 (2017)
  9. MCC950, the selective NLRP3 inflammasome inhibitor protects mice against traumatic brain injury: S. Ismael, et al.; J. Neurotrauma 35,1294 (2017)
  10. Inhibitory Effect and Mechanism of Arctium lappa Extract on NLRP3 Inflammasome Activation: Y.K. Kim, et al.; Evid. Compl. Altern. Med. 6346734 (2018)
  11. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice: A.P. Perera, et al.; Sci. Rep. 8, 8618 (2018)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.